PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy.

Abstract Corneal endothelial cell (CEC) disorders, such as Fuchs's endothelial corneal dystrophy, induce abnormal corneal hydration and result in corneal haziness and vision loss known as bullous keratopathy. We investigated whether injection of cultured human CECs supplemented with a rho-associated protein kinase (ROCK) inhibitor into the anterior chamber could increase CEC density.
PMID
Related Publications

The Role of Rho Kinase Inhibitors in Corneal Endothelial Dysfunction.

The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction.

Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction.

Development of new therapeutic modalities for corneal endothelial disease focused on the proliferation of corneal endothelial cells using animal models.

ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue.

Authors

Mayor MeshTerms

Corneal Transplantation

Keywords
Journal Title the new england journal of medicine
Publication Year Start




PMID- 29539291
OWN - NLM
STAT- MEDLINE
DCOM- 20180323
LR  - 20180323
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 11
DP  - 2018 Mar 15
TI  - Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy.
PG  - 995-1003
LID - 10.1056/NEJMoa1712770 [doi]
AB  - BACKGROUND: Corneal endothelial cell (CEC) disorders, such as Fuchs's endothelial
      corneal dystrophy, induce abnormal corneal hydration and result in corneal
      haziness and vision loss known as bullous keratopathy. We investigated whether
      injection of cultured human CECs supplemented with a rho-associated protein
      kinase (ROCK) inhibitor into the anterior chamber could increase CEC density.
      METHODS: We performed an uncontrolled, single-group study involving 11 persons
      who had received a diagnosis of bullous keratopathy and had no detectable CECs.
      Human CECs were cultured from a donor cornea; a total of 1x10(6) passaged cells
      were supplemented with a ROCK inhibitor (final volume, 300 mul) and injected into
      the anterior chamber of the eye that was selected for treatment. After the
      procedure, patients were placed in a prone position for 3 hours. The primary
      outcome was restoration of corneal transparency, with a CEC density of more than 
      500 cells per square millimeter at the central cornea at 24 weeks after cell
      injection. Secondary outcomes were a corneal thickness of less than 630 mum and
      an improvement in best corrected visual acuity equivalent to two lines or more on
      a Landolt C eye chart at 24 weeks after cell injection. RESULTS: At 24 weeks
      after cell injection, we recorded a CEC density of more than 500 cells per square
      millimeter (range, 947 to 2833) in 11 of the 11 treated eyes (100%; 95%
      confidence interval [CI], 72 to 100), of which 10 had a CEC density exceeding
      1000 cells per square millimeter. A corneal thickness of less than 630 mum
      (range, 489 to 640) was attained in 10 of the 11 treated eyes (91%; 95% CI, 59 to
      100), and an improvement in best corrected visual acuity of two lines or more was
      recorded in 9 of the 11 treated eyes (82%; 95% CI, 48 to 98). CONCLUSIONS:
      Injection of human CECs supplemented with a ROCK inhibitor was followed by an
      increase in CEC density after 24 weeks in 11 persons with bullous keratopathy.
      (Funded by the Japan Agency for Medical Research and Development and others; UMIN
      number, UMIN000012534 .).
FAU - Kinoshita, Shigeru
AU  - Kinoshita S
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Koizumi, Noriko
AU  - Koizumi N
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Ueno, Morio
AU  - Ueno M
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Okumura, Naoki
AU  - Okumura N
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Imai, Kojiro
AU  - Imai K
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Tanaka, Hiroshi
AU  - Tanaka H
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Yamamoto, Yuji
AU  - Yamamoto Y
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Nakamura, Takahiro
AU  - Nakamura T
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Inatomi, Tsutomu
AU  - Inatomi T
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Bush, John
AU  - Bush J
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Toda, Munetoyo
AU  - Toda M
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Hagiya, Michio
AU  - Hagiya M
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Yokota, Isao
AU  - Yokota I
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Teramukai, Satoshi
AU  - Teramukai S
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Sotozono, Chie
AU  - Sotozono C
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
FAU - Hamuro, Junji
AU  - Hamuro J
AD  - From the Departments of Frontier Medical Science and Technology for Ophthalmology
      (S.K., T.N., M.T., M.H.), Ophthalmology (M.U., K.I., H.T., Y.Y., T.I., J.B.,
      C.S., J.H.), and Biostatistics (I.Y., S.T.), Kyoto Prefectural University of
      Medicine, and the Department of Biomedical Engineering, Doshisha University
      (N.K., N.O.) - both in Kyoto, Japan.
LA  - eng
SI  - UMIN CTR/UMIN000012534
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (rho-Associated Kinases)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2018 Mar 15;378(11):1057-1058. PMID: 29539278
MH  - Aged
MH  - Aged, 80 and over
MH  - Cells, Cultured
MH  - Combined Modality Therapy
MH  - Cornea/anatomy & histology/*cytology/surgery
MH  - Corneal Diseases/drug therapy/surgery/*therapy
MH  - *Corneal Transplantation
MH  - Endothelial Cells/metabolism/*transplantation
MH  - Female
MH  - Humans
MH  - Intraocular Pressure
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - rho-Associated Kinases/*antagonists & inhibitors
EDAT- 2018/03/15 06:00
MHDA- 2018/03/24 06:00
CRDT- 2018/03/15 06:00
PHST- 2018/03/15 06:00 [entrez]
PHST- 2018/03/15 06:00 [pubmed]
PHST- 2018/03/24 06:00 [medline]
AID - 10.1056/NEJMoa1712770 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Mar 15;378(11):995-1003. doi: 10.1056/NEJMoa1712770.